<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716248</url>
  </required_header>
  <id_info>
    <org_study_id>SMC-94</org_study_id>
    <nct_id>NCT00716248</nct_id>
  </id_info>
  <brief_title>Bucillamine Study of Holding Remission After Infliximab Dose-off</brief_title>
  <official_title>The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saitama Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Keio University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Saitama Medical University</source>
  <brief_summary>
    <textblock>
      Patients with rheumatoid arthritis who have been well controlled with methotrexate plus
      infliximab may remain in remission or low disease activity without infliximab. And the chance
      of sustained remission increase by the addition of another DMARD, bucillamine, at the time of
      discontinuing infliximab. The BuSHIDO trial is the prospective, randomized, controlled study
      comparing MTX monotherapy and MTX plus bucillamine combination therapy as to the rate of
      disease flare after discontinuing infliximab.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of disease flare</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bucillamine</intervention_name>
    <description>bucillamine 100 mg, twice a day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>methotrexate 6 mg or more per week</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RA according to American College of Radiology (ACR) classification criteria

          -  Age of 20 or greater

          -  DAS28-ESR &lt; 3.2 or DAS28-CRP &lt; 2.6 for more than 6 months

        Exclusion Criteria:

          -  Previously teated with bucillamine

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>January 4, 2011</last_update_submitted>
  <last_update_submitted_qc>January 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hideto Kameda</name_title>
    <organization>Department of Internal Medicine, School of Medicine, Keio University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Bucillamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

